Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Exagen Diagnostics to Present Six Scientific Posters at 2016 ACR/ARHP Annual Meeting

Posted on: 12 Oct 16

SAN DIEGO, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Exagen Diagnostics to feature six poster presentations on AVISE® testing at the American College of Rheumatology’s (ACR) annual meeting being held Nov. 11-16, 2016 in Washington, D.C. The AVISE family of tests includes AVISE CTD featuring patented biomarkers called cell-bound complement activation products (CB-CAPS) along with a proprietary index, all of which combines to offer enhanced detection for certain autoimmune rheumatic diseases including systemic lupus erythematosus (SLE). Attendees are invited to visit the Exagen booth #313 to learn more about the benefits of AVISE testing, including a new enhanced result report and the novel AVISE Touch specimen collection method. Abstracts can be seen online at the ACR website Titles, presentation dates and abstract numbers for the six featured posters are listed below.

Sunday, November 13, 2016:

Abstract Title: Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine. Presenter: Michelle Petri, MD. Abstract #751

Abstract Title: Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure as Compared to Etanercept. Presenter: Thierry Dervieux, PhD. Abstract #601

Tuesday, November 15, 2016:

Abstract Title: Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus. Presenter: James Mossell, MD. Abstract #2800

Abstract Title: Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus. Presenter: Daniel Wallace, MD. Abstract #2797

Abstract Title: Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus. Presenter: Richard Furie, MD. Abstract #2798

Abstract Title: Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus. Presenter: Hui-Yuen, MD. Abstract #2421

About Exagen

Exagen Diagnostics, Inc. is a College of American Pathologists (CAP) accredited and CLIA certified rheumatology specialty laboratory that focuses on the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of autoimmune connective tissue disease (CTD). Its groundbreaking solutions address the full continuum of care with tools designed and scientifically proven to help physicians deliver accurate, early diagnosis and optimized therapy. For more information, visit

About Lupus and Rheumatoid Arthritis

Lupus and rheumatoid arthritis are autoimmune diseases in which the body attacks its own, healthy tissues and organs. Patients suffer joint pain along with increased risk for other life threatening conditions. Systemic Lupus Erythematosus (SLE), a more severe form of lupus brings with it a host of unwanted symptoms including unexplained fevers, hair loss and fatigue, facial rashes. Women are more likely to suffer from these conditions it than men, and there’s no definitive cause, though researchers suspect genes as well as environmental factors may play a role.


Last updated on: 13/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.